The Food and Drug Administration today ordered manufacturers to immediately stop selling and distributing surgical mesh products for transvaginal repair of pelvic organ prolapse in the U.S. Women planning to have the procedure should discuss other treatment options with their doctors, and women who have had it should continue their routine follow-up care and notify their provider if they have complications or symptoms, FDA said. The agency reclassified the mesh devices as high risk in 2016, and required the two manufacturers — Boston Scientific and Coloplast — to submit premarket approval applications. “In order for these mesh devices to stay on the market, we determined that we needed evidence that they worked better than surgery without the use of mesh to repair [pelvic organ prolapse],” said Jeffrey Shuren, M.D., director of FDA’s Center for Devices and Radiological Health. “That evidence was lacking in these premarket applications, and we couldn’t assure women that these devices were safe and effective long term.”

Related News Articles

Headline
The Food and Drug Administration today reported 55 injuries and one death involving an infusion pump and vital signs monitoring system. Becton Dickinson…
Headline
The Food and Drug Administration today announced a voluntary pilot program to expedite approvals of certain changes to ethylene oxide sterilization processes…
Headline
The Food and Drug Administration should study potential alternatives to ethylene oxide for sterilizing medical devices, but a solution could be at least a…
Headline
The Food and Drug Administration today recommended medical device manufacturers, health care providers and patients take certain actions to reduce the risk…
Headline
To reduce risk of patient infection, the Food and Drug Administration recommends health care facilities transition to using duodenoscopes with disposable…
Headline
Medtronic has recalled certain MiniMed insulin pumps due to cybersecurity risks, and will provide alternative pumps to the estimated 4,000 U.S. patients using…